IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.357
NA - Nord America 776
EU - Europa 399
SA - Sud America 92
AF - Africa 20
OC - Oceania 13
Totale 5.657
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.409
US - Stati Uniti d'America 723
CN - Cina 512
HK - Hong Kong 297
GB - Regno Unito 102
DE - Germania 79
BR - Brasile 70
IT - Italia 59
CZ - Repubblica Ceca 54
VN - Vietnam 48
FI - Finlandia 25
IN - India 25
CA - Canada 23
MX - Messico 22
NL - Olanda 18
AU - Australia 12
ID - Indonesia 12
ZA - Sudafrica 12
AR - Argentina 9
JP - Giappone 9
PL - Polonia 9
BD - Bangladesh 8
FR - Francia 7
UA - Ucraina 7
BE - Belgio 6
PK - Pakistan 6
TR - Turchia 6
ES - Italia 5
PT - Portogallo 4
PY - Paraguay 4
TW - Taiwan 4
AL - Albania 3
AT - Austria 3
CL - Cile 3
EE - Estonia 3
LT - Lituania 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
CO - Colombia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GE - Georgia 2
IE - Irlanda 2
IQ - Iraq 2
MY - Malesia 2
NP - Nepal 2
PH - Filippine 2
RU - Federazione Russa 2
TN - Tunisia 2
UZ - Uzbekistan 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
EG - Egitto 1
GA - Gabon 1
IL - Israele 1
JO - Giordania 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
YE - Yemen 1
Totale 5.657
Salva come PNG Salva come JPEG
Città #
Singapore 314
Hong Kong 295
Ashburn 191
Hefei 183
Beijing 111
Boardman 106
London 82
Dallas 63
Shanghai 60
Munich 48
Brno 35
Los Angeles 35
Rome 30
Council Bluffs 29
San Francisco 26
Redmond 20
Pune 18
Amsterdam 17
Ho Chi Minh City 17
Mexico City 17
Olomouc 17
Turku 14
Seattle 13
São Paulo 12
Guangzhou 11
Hanoi 11
Helsinki 11
Santa Clara 11
Washington 11
New York 10
Toronto 10
Boston 9
Manchester 8
Tokyo 8
Brooklyn 7
Warsaw 7
Melbourne 6
Chicago 5
Ankara 4
Atlanta 4
Biên Hòa 4
Haikou 4
Haiphong 4
Johannesburg 4
Montreal 4
Campinas 3
Canberra 3
Chennai 3
Dhaka 3
Hangzhou 3
Hanover 3
Karachi 3
Mol 3
Oklahoma City 3
Paris 3
Rio de Janeiro 3
Stockholm 3
Sydney 3
Taipei 3
Tirana 3
Wuhan 3
Asunción 2
Aversa 2
Bismarck 2
Buenos Aires 2
Colombo 2
Concord 2
Curitiba 2
Dublin 2
Florence 2
Genoa 2
Grand Rapids 2
Hasselt 2
Iowa City 2
Jakarta 2
Kuala Lumpur 2
Lodz 2
Luoyang 2
Madrid 2
New Delhi 2
North Liberty 2
Nuremberg 2
Palermo 2
Phoenix 2
Porto 2
Quito 2
San José 2
Shanwei 2
Shenzhen 2
Tallinn 2
Tashkent 2
Tbilisi 2
The Dalles 2
Thái Nguyên 2
Topeka 2
Vilnius 2
West Jordan 2
Xi'an 2
Xiamen 2
Zhengzhou 2
Totale 2.032
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 206
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 189
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 188
Cancer drugs and QT prolongation: weighing risk against benefit 186
Minimal sampling colistin pharmacokinetics in critically ill patients 186
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 182
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 182
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 176
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 173
Cardio-oncology in clinical studies and real life 171
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 171
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 162
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 157
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 141
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 127
Anthracyclines 110
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 109
Anthracycline Cardiotoxicity 107
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 103
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 102
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 100
Anthracycline Cardiotoxicity 92
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 88
An introduction to the metabolic determinants of anthracycline cardiotoxicity 85
Cardiotoxicity of antitumor drugs 76
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 71
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 71
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 71
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 56
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 55
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 55
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 48
Pharmacology of Cardio-Oncology 48
What is cardiotoxicity? 45
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 44
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 43
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 40
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 39
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 39
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 39
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 38
Isavuconazole: case report and pharmacokinetic considerations 37
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 37
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 37
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 36
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 36
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 36
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 35
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 35
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 33
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 32
Matters of the heart: The case of TNF-alpha targeting drugs 32
The concomitant management of cancer therapy and cardiac therapy 31
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 30
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 30
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 30
Pharmacological Foundation of Cardio-Oncology 29
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 28
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 28
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 28
Molecular determinants of the reduced cardiotoxicity of epirubicin 28
Doxorubicin degradation in cardiomyocytes 27
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 27
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 27
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 27
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 26
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 26
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 26
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 26
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 25
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 24
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 24
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 24
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 23
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 23
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 23
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 23
In ®Entresto we trust 23
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 23
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 22
Translating molecular mechanisms into clinical facts 22
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 22
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 22
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 22
Humans and Rodents: The Case of hOAT4 and mOat5 21
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 21
Do you know pixantrone? 19
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 19
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 19
The reality of pixantrone in real life 17
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 17
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 17
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 17
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 15
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 5.761
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/20261.111 336 204 131 250 139 51 0 0 0 0 0 0
Totale 5.761